A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and
PF 06826647 in Adults With Hidradenitis Suppurativa
Recruitment Status: recruiting as of August 2020.
Estimated Completion Date: Feb. 2, 2022
Sponsors and Collaborators: Pfizer
Information provided by (Responsible Party): Pfizer
Brief Summary: This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
Please link complete details https://clinicaltrials.gov/ct2/show/NCT04092452
Locations: multiple locations please refer to link above for further information.
Contact: Pfizer CT.gov Call Center, 1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com